The stock dropped 40 percent in the last year, but Knuckman sees some bullish signs. He explained that Teva is making new lows, but it's not making new highs in volatility. That is called a bullish divergence and it's often a sign the sellers are getting tired.
Knuckman added that the current administration in Washington is talking about cutting drugs cost and the best way to do that is with more generic drugs in the pipeline. He sees that as a good sign for Teva.
To make a bullish bet, Knuckman wants to buy the January 27.50 calls for $6. The trade breaks even at $33.50 or 4.39 percent above the current market price.
See more from Benzinga
- ConocoPhillips, Tesoro, Visa And Energy: Fast Money Picks For March 31
- Jim Cramer Weighs In On American Tower, Home Depot, Callaway Golf, Computer Sciences And Hewlett Packard Enterprise
- Mike Khouw Sees Unusual Options Activity In HCA Holdings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.